Gastrointestinal (GI) malignancies such as hepatocellular carcinoma, cholangiocarcinoma, and colorectal carcinoma are refractory to most current therapies and are among the largest cancer killers in the western world. While genomic technologies have cataloged many cancer-specific mutations, defining those changes that drive disease progression and represent potential therapeutic targets remains a significant unmet need. Genetically engineered mouse models (GEMMs) offer an ideal setting to interrogate the genetics and biology of cancer initiation and maintenance, and serve as powerful preclinical models to test novel cancer therapies. Nevertheless, the generation and analysis of new GEMMs using conventional methods is simply too slow and costly to evaluate even moderate numbers of candidate genes in vivo, and thus, genetic strategies to validate therapeutic targets in established tumors remain exceedingly challenging. Consequently, GEMM models have been underutilized in drug development efforts. Here we propose a conceptually new approach that enables rapid production of tailored, genetically defined animals in a fraction of the time of conventional methods. Our proposal is based on the derivation and use of disease-specific, multi-allelic embryonic stem cells (GEMM- ESCs) that can be customized to investigate any gene in a defined, disease-prone genetic background, without any breeding. Each model harbors a homing cassette that allows rapid targeting of tetracycline responsive short hairpin RNAs (shRNAs) constructs, allowing the production of cancer prone mice in which any gene can be suppressed in established tumors and normal tissue simply by the addition of doxycycline. This new modeling paradigm is built on a solid foundation of previous innovation in our laboratory that has led to improved RNAi and genome editing tools and will enable rapid evaluation of the potential efficacies and toxicities associated with target inhibition in vivo. Successful completion of the proposed work will dramatically increase the speed and scale at which genetic-associations and therapeutic targets can be investigated GI cancers and provide a paradigm that may transform the way we design and use mice in oncology research. As such, we believe our application meets all three major goals of the FOA, addressing one or more of the technical and experimental parameters that ensure effective translational use of mouse models as well as addressing unmet translational requirements. Our new models also will be ideally suited to contribute to, and benefit from, the Oncology Models Forum NCIP Hub platform.

Public Health Relevance

This project develops scalable and cost-effective GEMM-ESC models of lethal GI malignancies to produce a resource for the genetic validation of single and combination targets in established GI cancers and to enable a first pass assessment potential toxicities to normal tissues. The project will produce new tools for interrogating gene function in GI cancers that will be broadly useful to the oncology research community.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA195787-01
Application #
8903652
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Eljanne, Mariam
Project Start
2015-07-01
Project End
2018-06-30
Budget Start
2015-07-01
Budget End
2016-06-30
Support Year
1
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Redelman-Sidi, Gil; Binyamin, Anna; Gaeta, Isabella et al. (2018) The Canonical Wnt Pathway Drives Macropinocytosis in Cancer. Cancer Res 78:4658-4670
Livshits, Geulah; Alonso-Curbelo, Direna; Morris 4th, John P et al. (2018) Arid1a restrains Kras-dependent changes in acinar cell identity. Elife 7:
Krishnamoorthy, Gnana P; Davidson, Natalie R; Leach, Steven D et al. (2018) EIF1AX and RAS mutations cooperate to drive thyroid tumorigenesis through ATF4 and c-MYC. Cancer Discov :
Zafra, Maria Paz; Schatoff, Emma M; Katti, Alyna et al. (2018) Optimized base editors enable efficient editing in cells, organoids and mice. Nat Biotechnol 36:888-893
Schatoff, Emma M; Leach, Benjamin I; Dow, Lukas E (2017) Wnt Signaling and Colorectal Cancer. Curr Colorectal Cancer Rep 13:101-110
Sakamaki, Jun-Ichi; Wilkinson, Simon; Hahn, Marcel et al. (2017) Bromodomain Protein BRD4 Is a Transcriptional Repressor of Autophagy and Lysosomal Function. Mol Cell 66:517-532.e9
O'Rourke, Kevin P; Loizou, Evangelia; Livshits, Geulah et al. (2017) Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer. Nat Biotechnol 35:577-582
Han, Teng; Schatoff, Emma M; Murphy, Charles et al. (2017) R-Spondin chromosome rearrangements drive Wnt-dependent tumour initiation and maintenance in the intestine. Nat Commun 8:15945
Pelossof, Raphael; Fairchild, Lauren; Huang, Chun-Hao et al. (2017) Prediction of potent shRNAs with a sequential classification algorithm. Nat Biotechnol 35:350-353
Baker, Leena; BeGora, Michael; Au Yeung, Faith et al. (2016) Scribble is required for pregnancy-induced alveologenesis in the adult mammary gland. J Cell Sci 129:2307-15

Showing the most recent 10 out of 18 publications